10-Q: Reviva Pharma Faces Delisting Amid Q3 Loss, Brilaroxazine Progress

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss in Q3 2025 and advanced its lead drug candidate brilaroxazine, but faces Nasdaq delisting concerns and ongoing liquidity challenges.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $4.0 million from $8.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased to $16.5 million from $23.7 million in the prior year period.
• Research and development expenses significantly decreased by 68.9% for the three months and 45.3% for the nine months ended September 30, 2025, primarily due to the wind-down of the OLE trial.
• The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine in schizophrenia, with positive long-term safety, tolerability, and efficacy data.
• A meeting with the FDA is planned for Q4-2025 to discuss NDA submission for brilaroxazine based on existing data, targeting Q2-2026 for submission if the FDA response is positive.
• The company raised approximately $0.5 million net from its ATM offering, $9.0 million net from its June 2025 public offering, and $8.1 million net from its September 2025 public offering.
• Post-period, in October and November 2025, the company issued 18,721,500 shares from warrant exercises, generating approximately $6.4 million in gross proceeds.
• As of September 30, 2025, cash and cash equivalents were $13.2 million, and the accumulated deficit was $180.8 million.
• The company received a notice on November 11, 2025, from Nasdaq regarding potential delisting due to non-compliance with the $1.00 minimum bid price requirement and ineligibility for a further extension.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to identified material weaknesses in internal control over financial reporting.

Sentiment

Score: 3

Explanation: While the clinical trial results for brilaroxazine are positive and the net loss has decreased, the severe liquidity issues, explicit 'going concern' doubt, and the immediate threat of Nasdaq delisting create significant negative sentiment. The material weaknesses in internal controls further compound these concerns, overshadowing the clinical progress and recent capital raises which are insufficient to address long-term needs.

Positives

• Net loss significantly decreased for both the three-month ($4.0 million vs. $8.4 million) and nine-month ($16.5 million vs. $23.7 million) periods ended September 30, 2025, compared to the prior year.
• Successful completion of the Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine in schizophrenia, demonstrating robust broad-spectrum efficacy sustained over one year and a generally well-tolerated safety profile.
• Planned meeting with the FDA in Q4-2025 to discuss NDA submission for brilaroxazine based on existing data, potentially accelerating the path to market.
• Significant capital raised through public offerings and ATM sales in June and September 2025, totaling approximately $17.6 million net, plus $6.4 million gross from warrant exercises post-period.
• Working capital surplus increased substantially to $3.8 million as of September 30, 2025, from $81,861 at December 31, 2024.
• Research and development expenses decreased significantly, reflecting the wind-down of the OLE trial, which could indicate a more focused approach or completion of costly trial phases.

Negatives

• The company has incurred losses since inception and expects to continue incurring significant expenses and operating losses for the foreseeable future.
• Current cash on hand ($13.2 million as of September 30, 2025) is not sufficient to satisfy operating cash needs for the next 12 months from the filing date, requiring additional fundraising in fiscal year 2026.
• Conditions raise substantial doubt regarding the company's ability to continue as a going concern for a period of one year after the financial statements are issued.
• Received a notice from Nasdaq on November 11, 2025, indicating potential delisting due to non-compliance with the $1.00 minimum bid price requirement and ineligibility for a second 180-day compliance period.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting, including an ineffective control environment and IT general controls.
• Accumulated deficit increased to $180.8 million as of September 30, 2025, from $164.3 million at December 31, 2024.
• Significant dilution occurred with common stock outstanding increasing from 46,579,199 shares at December 31, 2024, to 96,337,119 shares at September 30, 2025, and further to 115,058,619 shares as of November 11, 2025.

Risks

• Inability to obtain necessary financing to continue business operations, conduct ongoing and planned trials, and complete development and commercialization of product candidates.
• Failure of current or planned clinical trials to achieve desired results, or inability to complete requisite regulatory review and approval processes.
• The possibility of being forced to delay, reduce, or eliminate planned clinical trials or development programs.
• Inability to obtain approval from regulatory agents in different jurisdictions for current or future product candidates.
• Inability to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market, leading to potential delisting and negative impact on stock price and access to capital markets.
• Disruptions at the FDA and other government agencies caused by funding shortages (e.g., government shutdowns) could hinder timely review and approval of regulatory submissions.
• The valuation of private common warrants could increase volatility in net income (loss).
• Exposure to liability, protracted and costly litigation, or reputational damage relating to data security.
• Material weaknesses identified in internal control over financial reporting could lead to disruptions and misstatements.
• Dependence on third-party suppliers and manufacturers, and the ability to find additional or alternative sources.

Future Outlook

The company expects to incur significant expenses and increased operating losses for the next several years as it continues to research, develop, and commercialize its product candidates. It anticipates needing additional fundraising activities and cash on hand during the 2026 fiscal year, as current cash is only sufficient into the second quarter of 2026. A meeting with the FDA is planned for Q4-2025 to discuss NDA submission for brilaroxazine, with a target submission in Q2-2026 if the FDA response is positive. A potential Phase 3 RECOVER-2 Trial may be initiated in early 2026 if required by the FDA. The company is committed to improving its internal control over financial reporting and IT general controls.

Management Comments

• We believe that we have adequate cash on hand to cover anticipated outlays into the second quarter of 2026 but will need additional fundraising activities and cash on hand during the 2026 fiscal year.
• We intend to secure such additional funding, although there are no guarantees or commitments for additional funding.
• We believe we have successfully completed with positive results the two randomized double blind trials, as well as the safety, pharmacology and non-clinical studies typically required for NDA approval.
• We are preparing to meet with FDA to gain alignment on our path to NDA submission, including a discussion of whether there is a need for a second phase 3 study (RECOVER-2).
• If FDA tells us we need to initiate a second phase 3 study, we intend to commence it in early 2026, subject to financing.
• We are committed to continuing to improve our internal control over financial reporting, and also our IT general controls.

Industry Context

As a clinical-stage biopharmaceutical company, Reviva Pharmaceuticals operates in a high-risk, high-reward industry characterized by significant R&D investment, lengthy clinical trials, and stringent regulatory approval processes. The successful completion of Phase 3 trials for brilaroxazine positions the company closer to potential commercialization, a critical milestone for any drug developer. However, the ongoing need for substantial capital, coupled with a history of operating losses and the 'going concern' doubt, is typical for companies at this stage, highlighting the inherent financial challenges in bringing new therapies to market. The Nasdaq delisting threat adds an additional layer of uncertainty, which is a common challenge for smaller biotech firms struggling with market capitalization and share price volatility.

Comparison to Industry Standards

• The successful completion of a Phase 3 OLE trial for brilaroxazine in schizophrenia, demonstrating sustained efficacy and a well-tolerated safety profile over one year, is a positive indicator, aligning with the rigorous data requirements for CNS drug development. For example, similar late-stage antipsychotic drug candidates from companies like Karuna Therapeutics (KarXT) or Acadia Pharmaceuticals (Pimavanserin) have also emphasized long-term safety and efficacy in their clinical programs to support regulatory submissions.
• The planned Q4-2025 meeting with the FDA to discuss NDA submission based on existing data, potentially bypassing a second Phase 3 trial (RECOVER-2), could significantly accelerate time-to-market, a key competitive advantage in the pharmaceutical industry. This strategy, if successful, would be comparable to accelerated approval pathways or situations where robust data from fewer pivotal trials are deemed sufficient, as seen with some orphan drugs or therapies addressing high unmet needs.
• The company's accumulated deficit of $180.8 million and ongoing operating losses are typical for clinical-stage biopharmaceutical companies, which often require extensive capital investment over many years before generating revenue. This financial profile is common among peers focused on CNS drug development, where R&D cycles are long and expensive.
• The Nasdaq delisting notice due to minimum bid price non-compliance is a recurring issue for smaller-cap biotech companies, especially those without commercialized products. Many emerging biotechs face similar pressures and often resort to reverse stock splits to maintain listing, a strategy that can be viewed negatively by investors but is sometimes necessary for continued access to public markets.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims.

Stakeholder Impact

• **Shareholders:** Face significant dilution from recent and ongoing capital raises, potential negative impact on share price from Nasdaq delisting threat, and uncertainty regarding the company's ability to continue as a going concern. Positive clinical data offers long-term potential but is currently overshadowed by immediate financial and listing risks.
• **Employees:** The company's 'going concern' doubt and need for further financing could create job insecurity. Stock-based compensation is a significant part of overall compensation, but its value is tied to the volatile stock price and listing status.
• **Customers (future):** Successful NDA submission and commercialization of brilaroxazine would provide a new treatment option for patients with schizophrenia and potentially other CNS, inflammatory, and cardiometabolic diseases.
• **Suppliers/Vendors:** The company's financial health and 'going concern' doubt could impact its ability to meet payment obligations or secure favorable terms for future contracts, particularly for clinical trial services and manufacturing.
• **Creditors:** The 'going concern' doubt and need for additional financing increase the risk profile for any current or future lenders.

Next Steps

• Conduct a planned meeting with the FDA in Q4-2025 to discuss NDA submission for brilaroxazine.
• Target NDA submission for brilaroxazine in Q2-2026 if the FDA response is positive.
• Potentially initiate a Phase 3 RECOVER-2 Trial in early 2026 if required by the FDA.
• Continue efforts to raise additional funds through public or private equity, debt financings, or collaborations to support ongoing development and operations.
• Timely request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination and seek an extension.
• Monitor the closing bid price of common stock and consider a reverse stock split if necessary to regain Nasdaq compliance.
• Continue to implement remediation procedures for identified material weaknesses in internal control over financial reporting, including engaging a third-party consulting firm and realigning personnel.

Key Dates

Recommendation

Despite positive clinical trial results for brilaroxazine, the company faces immediate and severe existential threats. The explicit 'substantial doubt regarding the Company’s ability to continue as a going concern' is a red flag, indicating a high risk of insolvency or significant restructuring. The Nasdaq delisting notice, with the company being ineligible for a further extension, presents an imminent threat to liquidity and investor confidence. Furthermore, the identified material weaknesses in internal controls suggest fundamental operational and governance deficiencies. While recent capital raises provide some short-term relief, they are insufficient to address the long-term funding needs, and the significant dilution incurred by existing shareholders is a concern. The combination of severe liquidity risk, imminent delisting, and internal control failures makes the stock a strong sell, as the downside risks far outweigh the speculative upside from clinical progress.

Keywords

Reviva Pharmaceuticals, RVPH, 10-Q, Quarterly Report, Brilaroxazine, Schizophrenia, Clinical Trials, Phase 3 RECOVER, OLE Trial, NDA Submission, FDA, Biopharmaceutical, Drug Development, Nasdaq Delisting, Going Concern, Capital Raise, Warrants, Internal Controls, CNS diseases, Inflammatory diseases, Cardiometabolic diseases